Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

GordoHLYK13 Aug. 14 at 2:19 PM

$IGC is entering a historic inflection point—with its first true Phase 2 binary catalyst, advancing regulatory infrastructure, and growing clinical-data capabilities, a successful CALMA readout could dramatically re-rate the company and unlock a whole new valuation tier. 🚀📈 $PFE $ABBV

0 · Reply

chop14 Aug. 14 at 2:15 PM

$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY

0 · Reply

pineconecameo Aug. 14 at 2:07 PM

$PFE back to $27 and $NVDA $230 ♻️

0 · Reply

Micheal_Pothead Aug. 14 at 1:55 PM

$PFE another reminder that max pain today is 26.50 🫩

0 · Reply

Makingmillions192 Aug. 14 at 1:55 PM

$LEXX More info on our new partner… PegBio (PegBio Co., Ltd.) is a publicly traded biopharmaceutical company founded in 2008 and based in Hangzhou, China. It focuses on discovering and developing long-acting therapeutic drugs for metabolic and chronic conditions like type-2 diabetes and obesity using specialized PEGylation technology. Key Products and PipelinePB-119 (Visepegenatide): A long-acting GLP-1 receptor agonist designed for once-weekly diabetes management, which gained approval and commercialization in China. Other Candidates: The company develops additional pipeline assets—such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309—targeting obesity, diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Recent Partnerships: PegBio entered a material transfer agreement with Lexaria Bioscience to evaluate oral delivery applications using DehydraTECH technology for proprietary GLP-1 molecules. $LLY $NVO $PFE $AMGN

0 · Reply

Micheal_Pothead Aug. 14 at 1:36 PM

$PFE lmfao

0 · Reply

JuggernautRaider Aug. 14 at 1:26 PM

$TNXP eh….. i like $BMY $PFE and $GILD . Tonix is run like 💩 Do your own @Duediligence20 hmm Who has been following me? I need to delete this and get outta here 👍 ☘️ 🫡 🇺🇸 🚘 ⚡️ 🚀

0 · Reply

Micheal_Pothead Aug. 14 at 1:11 PM

$PFE where we closing today?

2 · Reply

TraderDaKing Aug. 14 at 12:00 PM

$ELTP $DJT $GME $PFE $WEN Great News. THIS IS THE MOST IMPORTANT THING WE GOT FROM THE 10Q Date: 8/13/2026 Form: 10-Q - Quarterly Report NOTE 9. COMMITMENTS AND CONTINGENCIES On August 17, 2023, Elite filed a paragraph IV certification with its ANDA to generic OxyContin® and after Elite got acceptance of the ANDA by the FDA on September 19, 2023, Elite sent the patentee and NDA holder a Notice Letter as required under the Hatch-Waxman Act. On November 14, 2023, a patent infringement suit was filed in the District Court of New Jersey by Purdue Pharma. The Parties agreed to a stipulated dismissal of the case and the judge signed the order dismissing the case on June 12, 2026. Elite’s launch of a generic OxyContin® will depend on the approval by the FDA. WILL TRUMP AND RFKJR ON OUR SIDE WE READY FOR THE NEXT LEVEL. ( up-listing ) and merger and or partnership. I'm buying all I can today. This is what I was looking for.

1 · Reply

CharlieeMungerTWITS Aug. 14 at 11:40 AM

$CELC I call it now - $PFE will acquire celc because there’s no reason to collect 14% on an fda approved drug that will generate $3B. NCCN inclusion ahead of commercial launch is significant. It helps establish REVTORPYK in the treatment pathway before Celcuity even begins the full commercial rollout. * $30,000 per cycle WAC is substantial. That’s roughly a 25% premium to Piqray, according to the Needham note. Management had previously telegraphed premium pricing, so they’re apparently getting it. Before pricing was announced, Leerink had estimated around $29K/month. * 9.0–9.7 months treatment duration is encouraging commercially. At $30K/cycle, duration matters enormously to eventual revenue per patient. * Expanded Access Program before launch means physicians can begin getting experience with REVTORPYK rather than everything waiting for the late-Q3 commercial launch.

1 · Reply